Navigation Links
Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
Date:6/2/2009

Only 41 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources

Patient-Flow Models Need to Take Into Account Effexor XR's More Frequent Use in Early Lines of Therapy Compared With Cymbalta

WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that one third of surveyed psychiatrists and two thirds of primary care physicians (PCPs) expect to increase their use of serotonin-norepinephrine reuptake inhibitors (SNRIs) over the next two years for the treatment of generalized anxiety disorder (GAD). Patient-level claims data show that benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) dominate early lines of treatment. However, the frequent onset of side effects, including sexual dysfunction, often lead to patients progressing to subsequent lines of therapy. Patients often try multiple SSRIs before switching to a new drug class.

"Our physician survey results suggest physicians turn to SNRIs following the failure of SSRI therapy. Although SSRIs and SNRIs are considered to have similar efficacy, the use of SNRIs is limited by formulary restrictions," stated Amanda Puffer, M.Sc., analyst at Decision Resources. "With the availability of Wyeth's Effexor XR in generics in December 2010, surveyed psychiatrists and PCPs anticipate a decrease in their first-line use of many SSRIs and an increase in their use of SNRIs as a monotherapy."

The new report entitled Treatment Algorithms in Generalized Anxiety Disorder also finds that only 41.8 percent of newly diagnosed GAD patients receive a drug within one year of their first diagnosis. Surveyed physicians indicate that this could be due to their or the patient's belief that symptoms are not severe enough to warrant a prescription and fear of side effects.

Patient-flow analysis for GAD shows that Effexor XR is used more frequently than Eli Lilly's Cymbalta following the failure of SSRIs in early lines of treatment. Patient-flow models of Cymbalta, Effexor XR and other branded agents are critical for forecasting patient-flow to generate more accurate estimates of the potential pool of customers for a given brand in this highly genericized market.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
4. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
5. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
6. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
7. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
8. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
9. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... OncLive® , a leading digital provider ... University of Virginia (UVA) Cancer Center to its quickly expanding Strategic ... will publicize and promote public awareness of UVA Cancer Center’s latest advances in ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... organization to provide strategic sales leadership and to further develop their rapidly expanding ... B.S. in Business Administration with a concentration in Marketing and an M.B.A. with ...
(Date:5/26/2016)... ... ... Dr. LeRoy Perry’s recently authored whitepaper, “Tech Neck and ROI (return on ... users, hundreds of millions of whom are coming into the workplace with pain in ... action of looking down at hand-held technology devices (tablets, smartphones) for extended periods of ...
(Date:5/26/2016)... ... , ... In 1980, Bill Howe opened AM/PM Sewer and Drains as a ... to grow the company was built on a simple mission of providing qualified San ... and customer service. Over 35 years later, Bill Howe remains one of the largest ...
(Date:5/26/2016)... ... May 26, 2016 , ... TopConsumerReviews.com ... Blood Pressure products . , High blood pressure affects millions of people worldwide, ... blood pressure can lead to heart disease, stroke, kidney disease, and hardening of ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... According to a new market report ... U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 ... was valued at US$ 5.89 Bn in 2014 and is ... to 2023 to reach US$ 7.99 Bn in 2023. ... needle free drug delivery devices and the market is estimated ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
Breaking Medicine Technology: